Novel Concepts for HIV Vaccine Vector Design

Overview

Journal mSphere

Publisher American Society for Microbiology

Specialties Microbiology
Parasitology

Date 2017 Dec 16

PMID 29242831

Citations 7

Authors

Quazim A Alayo

Nicholas M Provine

Pablo Penaloza-MacMaster

Affiliations

Soon will be listed here.

Abstract

The unprecedented challenges of developing effective vaccines against intracellular pathogens such as HIV, malaria, and tuberculosis have resulted in more rational approaches to vaccine development. Apart from the recent advances in the design and selection of improved epitopes and adjuvants, there are also ongoing efforts to optimize delivery platforms. Viral vectors are the best-characterized delivery tools because of their intrinsic adjuvant capability, unique cellular tropism, and ability to trigger robust adaptive immune responses. However, a known limitation of viral vectors is preexisting immunity, and ongoing efforts are aimed at developing novel vector platforms with lower seroprevalence. It is also becoming increasingly clear that different vectors, even those derived from phylogenetically similar viruses, can elicit substantially distinct immune responses, in terms of quantity, quality, and location, which can ultimately affect immune protection. This review provides a summary of the status of viral vector development for HIV vaccines, with a particular focus on novel viral vectors and the types of adaptive immune responses that they induce.

Citing Articles

Fractionating a COVID-19 Ad5-vectored vaccine improves virus-specific immunity.

Sanchez S, Palacio N, Dangi T, Ciucci T, Penaloza-MacMaster P Sci Immunol. 2021; 6(66):eabi8635.

PMID: 34648369 PMC: 9278052. DOI: 10.1126/sciimmunol.abi8635.

Limiting the priming dose of a SARS CoV-2 vaccine improves virus-specific immunity.

Sanchez S, Palacio N, Dangi T, Ciucci T, Penaloza-MacMaster P bioRxiv. 2021; .

PMID: 33821275 PMC: 8020975. DOI: 10.1101/2021.03.31.437931.

Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice.

Wang J, Shu T, Deng W, Zheng Y, Liao M, Ye X J Virol. 2021; 95(12).

PMID: 33789991 PMC: 8315921. DOI: 10.1128/JVI.00059-21.

RhCMV serostatus and vaccine adjuvant impact immunogenicity of RhCMV/SIV vaccines.

Chang W, Deere J, Kieu H, Castillo L, Machmach K, Shen X Sci Rep. 2020; 10(1):14056.

PMID: 32820216 PMC: 7441386. DOI: 10.1038/s41598-020-71075-x.

Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector.

Giel-Moloney M, Esteban M, Oakes B, Vaine M, Asbach B, Wagner R Sci Rep. 2019; 9(1):20005.

PMID: 31882800 PMC: 6934588. DOI: 10.1038/s41598-019-56550-4.

References

Shiver J, Fu T, Chen L, Casimiro D, Davies M, Evans R . Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002; 415(6869):331-5. DOI: 10.1038/415331a. View

Fischer S, Graham M, Kuehnert M, Kotton C, Srinivasan A, Marty F . Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med. 2006; 354(21):2235-49. DOI: 10.1056/NEJMoa053240. View

Elbers A, Vecht U, Osterhaus A, Groen J, Wisselink H, Diepersloot R . Low prevalence of antibodies against the zoonotic agents Brucella abortus, Leptospira spp., Streptococcus suis serotype II, hantavirus, and lymphocytic choriomeningitis virus among veterinarians and pig farmers in the southern part of The Netherlands. Vet Q. 1999; 21(2):50-4. DOI: 10.1080/01652176.1999.9694991. View

Mueller S, Matloubian M, Clemens D, Sharpe A, Freeman G, Gangappa S . Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc Natl Acad Sci U S A. 2007; 104(39):15430-5. PMC: 2000533. DOI: 10.1073/pnas.0702579104. View

Rolland M, Edlefsen P, Larsen B, Tovanabutra S, Sanders-Buell E, Hertz T . Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012; 490(7420):417-20. PMC: 3551291. DOI: 10.1038/nature11519. View

Parks C, Picker L, King C . Development of replication-competent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS. 2013; 8(5):402-11. PMC: 4040527. DOI: 10.1097/COH.0b013e328363d389. View

Malkevitch N, Patterson L, Aldrich K, Richardson E, Alvord W, Robert-Guroff M . A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in.... J Immunol. 2003; 170(8):4281-9. DOI: 10.4049/jimmunol.170.8.4281. View

Keefer M, Frey S, Elizaga M, Metch B, De Rosa S, Barroso P . A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine. 2011; 29(10):1948-58. PMC: 3043112. DOI: 10.1016/j.vaccine.2010.12.104. View

Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A . Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012; 4(115):115ra2. PMC: 3627206. DOI: 10.1126/scitranslmed.3002925. View

10.

Nyombayire J, Anzala O, Gazzard B, Karita E, Bergin P, Hayes P . First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. J Infect Dis. 2017; 215(1):95-104. PMC: 5225252. DOI: 10.1093/infdis/jiw500. View

11.

Santra S, Liao H, Zhang R, Muldoon M, Watson S, Fischer W . Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med. 2010; 16(3):324-8. PMC: 2834806. DOI: 10.1038/nm.2108. View

12.

Provine N, Larocca R, Penaloza-MacMaster P, Borducchi E, McNally A, Parenteau L . Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses. J Immunol. 2014; 192(11):5214-25. PMC: 4025612. DOI: 10.4049/jimmunol.1302806. View

13.

McShane H . Developing an improved vaccine against tuberculosis. Expert Rev Vaccines. 2004; 3(3):299-306. DOI: 10.1586/14760584.3.3.299. View

14.

Maxfield L, Abbink P, Stephenson K, Borducchi E, Nganga D, Kirilova M . Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization. Clin Vaccine Immunol. 2015; 22(11):1166-75. PMC: 4622110. DOI: 10.1128/CVI.00510-15. View

15.

Summerford C, Samulski R . Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol. 1998; 72(2):1438-45. PMC: 124624. DOI: 10.1128/JVI.72.2.1438-1445.1998. View

16.

Eloit M, Toma B, Perricaudet M . Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine. J Gen Virol. 1990; 71 ( Pt 10):2425-31. DOI: 10.1099/0022-1317-71-10-2425. View

17.

Janssen E, Lemmens E, Wolfe T, Christen U, von Herrath M, Schoenberger S . CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003; 421(6925):852-6. DOI: 10.1038/nature01441. View

18.

Sarkar S, Kalia V, Nicholas Haining W, Konieczny B, Subramaniam S, Ahmed R . Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates. J Exp Med. 2008; 205(3):625-40. PMC: 2275385. DOI: 10.1084/jem.20071641. View

19.

Ndhlovu Z, Chibnik L, Proudfoot J, Vine S, McMullen A, Cesa K . High-dimensional immunomonitoring models of HIV-1-specific CD8 T-cell responses accurately identify subjects achieving spontaneous viral control. Blood. 2012; 121(5):801-11. PMC: 3563365. DOI: 10.1182/blood-2012-06-436295. View

20.

Hammer S, Sobieszczyk M, Janes H, Karuna S, Mulligan M, Grove D . Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013; 369(22):2083-92. PMC: 4030634. DOI: 10.1056/NEJMoa1310566. View